A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

147 sites for NCT04293562

BCR-ABL1 Fusion, +48 more biomarkers

Acute Myeloid Leukemia

allogeneic hematopoietic stem cell transplantation, +12 more drugs

cellular therapy, +4 more types

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

198 sites for NCT04102020

BCR-ABL1 Fusion, +47 more biomarkers

Acute Myeloid Leukemia

azacitidine, +1 more drug

chemotherapy

Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL/SLL Study

316 sites for NCT04269902

Complex karyotype, +1 more biomarker

Chronic Lymphocytic Leukemia, +1 more condition

obinutuzumab, +1 more drug

chemotherapy, +1 more type

Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

1 site for NCT04708054

ARAF Mutation, +47 more biomarkers

Acute Myeloid Leukemia, +2 more conditions

busulfan, +5 more drugs

cellular therapy, +1 more type

Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

1 site for NCT01085617

BCR-ABL1 Fusion, +5 more biomarkers

B-Cell Acute Lymphoblastic Leukemia, +1 more condition

cyclophosphamide, +12 more drugs

chemotherapy, +2 more types

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Acute Leukemia After T Cell Depleted Allo-HSCT

1 site for NCT04959903

ABL1 Fusion, +69 more biomarkers

Acute Lymphoblastic Leukemia, +1 more condition

allogeneic hematopoietic stem cell transplantation

cellular therapy

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

1 site for NCT04526288

CBL Loss, +95 more biomarkers

Acute Myeloid Leukemia, +2 more conditions

allogeneic hematopoietic stem cell transplantation, +1 more drug

cellular therapy, +1 more type

A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML

2 sites for NCT03846362

Complex karyotype, +6 more biomarkers

Acute Myeloid Leukemia

allogeneic hematopoietic stem cell transplantation

cellular therapy

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

2 sites for NCT04269213

Complex karyotype, +26 more biomarkers

Acute Myeloid Leukemia, +3 more conditions

liposome-encapsulated daunorubicin-cytarabine

chemotherapy

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

1 site for NCT04169737

Complex karyotype, +5 more biomarkers

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

acalabrutinib, +2 more drugs

chemotherapy, +2 more types

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

1 site for NCT03849651

BCR-ABL1 Fusion, +56 more biomarkers

Acute Biphenotypic Leukemia, +12 more conditions

cyclophosphamide, +6 more drugs

cellular therapy, +2 more types

Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma

1 site for NCT02727803

BCR-ABL1 Fusion, +56 more biomarkers

Acute Biphenotypic Leukemia, +16 more conditions

anti-thymocyte globulin, +11 more drugs

cellular therapy, +4 more types